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Abstract
Objective—To assess ovarian follicle function in women with 46,XX spontaneous primary ovarian
insufficiency
Design—Case-control with nested prospective cohort
Setting—Clinical Research Center, National Institutes of Health
Patients—Women with primary ovarian insufficiency without estrogen replacement for two weeks
(N=97) and regularly menstruating control women (N=42)
Interventions—Single injection of 300 IU hrFSH
Main outcome measures—Change in serum estradiol at 24 hours
Results—Antral follicles ≥ 3 mm were detected in 73% (69/95) of patients; both serum estradiol
and progesterone levels correlated significantly with maximum follicle diameter in these women.
Patients with a maximum follicle diameter ≥ 8 mm had significantly higher serum estradiol and
progesterone levels and significantly lower FSH and LH levels as compared to patients without such
follicles. In controls estradiol levels increased significantly after FSH administration but in patients
this was not the case despite the presence of an antral follicle ≥ 8 mm.
Conclusion—Most women with 46,XX spontaneous primary ovarian insufficiency have antral
follicles detectable by ultrasound, suggesting that down-regulation of FSH receptors is not the
predominant mechanism of follicle dysfunction. Evidence of progesterone secretion by antral
follicles ≥ 8 mm in these patients is consistent with prior histologic evidence that follicle luteinization
is the predominant mechanism of follicle dysfunction in this condition. Prospective controlled
investigation designed to improve ovulatory function and fertility in these women is indicated.
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Introduction
Menopause, defined as the permanent cessation of menses and irreversible termination of
fertility, develops due to a depletion of potentially functional primordial follicles (1). Normal
ovarian function depends on the presence of functional primordial follicles. The ovary is unique
in the endocrine system in that it develops an entirely new secretory structure each month. This
secretory structure, the Graafian follicle, arises from a primordial follicle. The maximum
number of germ cells in the ovary peaks at about 7 million during week 20 of gestation. At
birth the follicle count is approximately 2 million and at puberty approximately 400,000 (2).
In 1942 Fuller Albright et al. first reported a syndrome in young women that was characterized
by amenorrhea and estrogen deficiency in association with menopausal FSH levels (3). He
termed the condition “primary ovarian insufficiency” to make clear that it was ovarian function
that was the primary defect rather than failure of FSH secretion by the pituitary (secondary
ovarian insufficiency). Some women with this condition conceive years after the diagnosis,
and for this reason the term “primary ovarian insufficiency” is more accurate, and may be less
stigmatizing than the terms “premature menopause” and “premature ovarian failure” (4–6).
In 1982 Coulam reported that primordial follicles were found in ovarian biopsies in only 5 of
81 patients (6%) with 46,XX primary ovarian insufficiency (7). However, many women with
primary ovarian insufficiency are known to experience intermittent and unpredictable ovarian
function (8–12). In fact, over a 4 month period of serial sampling 50% of women with 46,XX
spontaneous primary ovarian insufficiency had evidence of ovarian follicle function as defined
by a serum estradiol level greater than 50 pg/ml (10). However, only four percent of women
ovulated per month. We have previously demonstrated by ovarian biopsy and histologic
examination that women with 46,XX spontaneous primary ovarian insufficiency frequently
develop lutienized graafian follicles (10). Insight into the mechanisms that prevent most of
these follicles from becoming ovulatory might lead to development of treatments to restore
fertility.
The a priori aim of this study was to characterize the Graafian follicle function in response to
FSH stimulation in women with 46,XX spontaneous primary ovarian insufficiency. Normal
human follicles of 8mm in diameter or greater express aromatase and should secrete estradiol
in response to FSH stimulation (13,14). We tested the hypothesis that women with primary
ovarian insufficiency who have a follicle equal to or greater than 8 mm in diameter will respond
to FSH stimulation by significantly increasing serum estradiol levels.
Material and Methods
The design of the study was case-control with a nested prospective cohort. From August 2000
to December 2005, we recruited women with 46, XX spontaneous primary ovarian
insufficiency and control women. Patients were recruited by letters to physicians, notices in
medical journals, and through the Internet. Controls were recruited by local advertisement. The
Institutional Review Board of the Eunice Kennedy Shriver National Institute of Child Health
and Human Development, National Institutes of Health (Bethesda, MD) approved the study.
Participants were compensated according to NIH guidelines. Guidelines for remuneration of
Hubayter et al. Page 2
Fertil Steril. Author manuscript; available in PMC 2011 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
research subjects in the NIH Intramural Research Program and registration in the clinical
research volunteer program database are available online (15).
Women with primary ovarian insufficiency
To be eligible for the study, patients had to meet the following inclusion criteria: 1) diagnosis
of spontaneous 46,XX primary ovarian insufficiency before the age of 40 years (i.e., at least 4
months of oligomenorrhea or amenorrhea and two FSH levels in the menopausal range, as
defined by the local laboratory, confirmed on two separate occasions, at least 1 month apart);
2) current age between 18 and 42; 3) no iatrogenic cause of primary ovarian insufficiency or
known chromosomal abnormality.
Controls
Control women were healthy, had a BMI ranging from 17 to 27, had a previous pregnancy,
were not pregnant at present, and were regularly menstruating (cycles between 21 and 35 days).
They reportedly did not smoke more than two cigarettes per day nor abuse alcohol (<two drinks
a day). They were taking no chronic medications, were not using hormonal contraception, and
were not exercising more than 10 hours a week. The control women had a serum progesterone
level exceeding 6 ng/ml in the menstrual cycle just before the study cycle.
Study Protocol—All participants denied any history of hypersensitivity to recombinant
FSH. All signed a written informed consent. Baseline serum levels were obtained for FSH,
LH, estradiol, and progesterone. We performed gray-scale and color Doppler transvaginal
ultrasound by using a multifrequency transducer (5–8 MHz) on a Sequoia scanner (Acuson,
Mountain View, CA) as reported previously (16). Scans were performed by two examiners
(DJ and EM). We defined antral follicles as anechoic structures at least 3 mm in diameter that
demonstrated no color flow. The baseline measurements were obtained on the third day of the
menstrual cycle in the control group and after 2 weeks off hormone replacement therapy in
women with primary ovarian insufficiency.
After baseline sampling we administered a single intramuscular dose of 300 IU of recombinant
human FSH (Organon, West Orange, NJ). This dose was chosen since it has been used in prior
studies to evaluate ovarian function (16,17). Repeat serum sampling was performed 24 hours
later.
The measurements of estradiol, FSH and LH levels were performed at the NIH Clinical Center.
Serum FSH and LH were analyzed by microparticle enzyme immunoassay (MEIA; Abbott
Laboratories Abbott Park, IL). FSH intra-assay CV was 4.9% and the inter-assay CV was 6.5%;
for LH these were 5.8% and 6.4%, respectively. Estradiol and progesterone were measured by
competitive chemiluminescence immunoassay (Immulite 2000 analyzer, Diagnostic Products
Corporation, Los Angeles, CA); intra-assay and inter-assay CV were <11.0% and <10%
respectively.
Statistical Analysis—We used the signed rank test and rank sum test for paired and unpaired
comparisons of populations. Correlation was assessed using the Spearman rank correlation.
To compare proportions in two populations we use Fisher’s exact test. To account for the
differences in age, age of onset of menstrual irregularity, age at diagnosis, and time since
diagnosis of primary ovarian insufficiency on the comparison of hormone levels between the
subgroups of patients defined by maximal follicle size, we used multivariate linear regression.
First we estimated an optimal Box-Cox transformation for each hormone and then fit a
multivariate regression to the transformed hormone values (18). This allowed us to test the
adjusted differences by using the Wald p-value for the term in the multivariate regression
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indicating whether or not the largest follicle was ≥8mm. All analyses used SAS version 9 (SAS,
Cary, NC). Statistical significance was set at the two-tailed level of P < 0.05.
Results
We recruited a total of 97 women with 46,XX spontaneous primary ovarian insufficiency and
42 healthy control women with regular menstrual cycles. Table 1 summarizes the baseline
characteristics of the participants. Women with primary ovarian insufficiency were
significantly younger than controls. There were no differences in BMI, age of menarche, or
racial/ethnic distribution. Only 3.1% (3/97) of women with spontaneous primary ovarian
insufficiency had primary amenorrhea.
All control women and 95 women (out of 97) with spontaneous primary ovarian insufficiency
had a sonographic evaluation (2 patients did not have the ultrasound). As shown in Table 1, as
expected, at baseline evaluation women with primary ovarian insufficiency had a higher serum
FSH and LH and significantly higher serum estradiol levels as compared to controls. Women
with spontaneous primary ovarian insufficiency had a significantly thinner endometrial stripe,
a smaller total ovarian volume, and a significantly smaller largest follicle diameter.
An antral follicle ≥ 3 mm was detected in 73% (69 out of 95) of women with 46,XX spontaneous
primary ovarian insufficiency. In these women there was a significant correlation between
follicle diameter and serum estradiol level (Figure 1) (N=66, as serum estradiol levels were
missing in 3 women). An antral follicle ≥ 8 mm was detected in 45% (43 out of 95). Basal
serum estradiol levels were significantly greater in patients who had an antral follicle ≥ 8 mm
as compared to women who did not have such follicles; the same was true for serum
progesterone levels (Table 2). Also, in those patients who had an antral follicle ≥ 3mm serum
progesterone levels correlated significantly with maximum follicle diameter (r=0.26, p=0.035).
As shown in Figure 2A, among 41 women with primary ovarian insufficiency who had a follicle
≥ 8 mm on sonogram and had serum estradiol measurement results available, the serum
estradiol did not increase significantly in response to FSH stimulation [median (interquartile
range, IQR) IU/L, 39.6 ( 21.9, 80.9) to 39.8 (20.0, 88.8)) pg/ml, P=0.190]. In contrast, serum
estradiol levels of control women significantly increased in response to FSH stimulation from
36.3 (28.0, 57.0) to 94.1 (67.0, 118.0) pg/ml (p < 0.001). Change in serum estradiol levels by
group are shown in Figure 2B. Controls had a significantly greater change in serum estradiol
in response to FSH stimulation when compared to patients. The estradiol response did not differ
significantly between those patients who had an antral follicle greater than 8 mm and those 48
who did not (p=0.95). When evaluating all women with spontaneous primary ovarian
insufficiency, the estradiol level increased in response to FSH marginally from median (IQR)
27.0 (20.0, 40.4) to 28.4 (20.0, 43.8) pg/ml, a rise of borderline significance (P=0.052).
Administration of FSH did not significantly change serum progesterone levels [median (IQR)
ng/ml 0.5 (0.3, 0.7) before vs. 0.5 (0.3, 0.7) after, p=0.111].
As shown in Table 2, when patients were segregated by the presence or absence of a follicle
8 mm in diameter or greater, significant differences were evident between the two groups.
Patients who had a follicle ≥ 8 mm were significantly older at the onset of menstrual
abnormality, older at the time of diagnosis, and had a shorter time interval since diagnosis.
Serum estradiol and progesterone levels were significantly greater and serum FSH and LH
were significantly lower in women with larger follicles. After these hormone levels were
adjusted for age, age of onset of menstrual irregularity, age at diagnosis, and time since
diagnosis of primary ovarian insufficiency, the estimated differences remained statistically
significant and in the same direction.
Hubayter et al. Page 4
Fertil Steril. Author manuscript; available in PMC 2011 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Discussion
As the pool of preantral follicles grow in response to endogenous FSH stimulation and then
reach an antral follicle size of approximately 8 mm in diameter or more, FSH dependent P450-
aromatase mRNA expression is significantly increased along with follicular production of
estradiol (13,19–22). In this prospective study of ovarian follicle function in women with 46,
XX spontaneous primary ovarian insufficiency, we found an antral follicle of 8 mm in diameter
or greater in nearly one-half of patients. The data lead us to conclude that these are indeed
follicles rather than non-functional cystic structures. Serum estradiol and progesterone levels
are significantly higher and serum FSH and LH levels are significantly lower in those patients
with antral follicles of this size. Furthermore, we found that serum estradiol levels are
significantly positively correlated with follicle diameter, which also supports a conclusion that
these structures are endocrinologically active. However, we show that these follicles respond
poorly to FSH stimulation as assessed by increase in measured serum estradiol level in response
to exogenous FSH.
The data lead us to conclude that some pathologic process is interfering with normal follicle
function in these patients. Clearly spontaneous 46,XX primary ovarian insufficiency in most
cases is not simply a situation of complete follicle depletion. As evidenced here, in many cases
this is a state of follicle dysfunction. It has been hypothesized that elevated FSH levels cause
down-regulation of FSH receptors in the ovaries of these patients (4,23,24). Down-regulation
of plasma membrane receptors may result from ligand-induced receptor internalization,
sequestration, and regulation of receptor mRNA levels (25). However, to our knowledge there
is no direct evidence demonstrating reduced FSH receptor expression in the follicles of young
women with 46,XX spontaneous primary ovarian insufficiency.
FSH action is unequivocally required to support follicular growth beyond the preantral antral
stage. Our findings lead us to conclude that FSH has been acting on the FSH receptor by two
lines of functional evidence: 1) follicles have grown beyond the preantral stage (which requires
FSH action), and 2) the follicles are associated with higher estradiol levels (which requires
FSH action to induce aromatase activity in granulosa cells). It seems reasonable to conclude
that FSH has been acting on its receptor. The fact that we detect antral follicles in 73% of these
patients and that we found a positive correlation between follicle diameter and serum estradiol
level are strong evidence that follicles are responding to FSH action by growing and secreting
steroids. Our data call into question the validity of the hypothesis that down-regulation of FSH
receptors is a common mechanism of follicle dysfunction in women with 46,XX spontaneous
primary ovarian insufficiency.
The requirement of FSH to stimulate follicle growth in humans was first demonstrated
elegantly by Rabin et al., wherein their investigation of a 22 year old woman with isolated FSH
deficiency showed no antral follicle development as assessed by laparoscopy and ovarian
biopsy (26). Subsequent clinical studies have confirmed the need for FSH to support follicle
development and estradiol production (27). This has also been confirmed in an animal model;
the FSH knockout mouse fails to develop follicles beyond the preantral stage (28). Furthermore,
ovarian biopsy in patients with a mutation in the FSH receptor has demonstrated the presence
of primordial follicles in 9 of 9 patients, but only one of these patients had an antral follicle
detected histologically (29). Based on the present data we conclude that preantral follicles in
most women with 46,XX spontaneous primary ovarian insufficiency are indeed capable of
responding to the abnormally high endogenous FSH stimulation with follicle growth and
estradiol production.
Another possible mechanism to explain the follicle dysfunction in this disorder deserves
consideration. The normal menopausal elevation of serum LH is known to result from
Hubayter et al. Page 5
Fertil Steril. Author manuscript; available in PMC 2011 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
inadequate negative feedback due to a reduced number of follicles (30). A properly timed LH
surge luteinizes a mature follicle, reduces granulosa cell mitogenic activity,(31) and induces
changes in steady state level of messenger ribonucleic acids for enzymes involved in
progesterone synthesis (32). Inappropriate early luteinization of a growing follicle would, thus,
be expected to impair follicle growth and reduce estradiol production in response to FSH.
We previously demonstrated histologically that inappropriate luteinization is a major
mechanism of follicle dysfunction in women with 46,XX spontaneous primary ovarian
insufficiency (10). This action on granulosa cells to cause lutienization is evidence that LH
receptors also have not been down-regulated by the high levels of serum LH in these patients.
Furthermore, the data presented here are not only consistent with the prior histologic evidence
of follicle luteinization in these patients but also supportive of this pathophysiologic
mechanism of follicle dysfunction. We found that serum progesterone level is positively
correlated with maximal follicle diameter in these women, which is convincing evidence that
the progesterone is indeed arising from the follicles. Also, patients with 8 mm or greater
follicles have serum progesterone levels significantly greater than those without such follicles.
The progesterone levels are understandably modest because these are luteinized follicles not
corpora lutea. Luteinization is a terminally differentiated state so that premature luteinization
expectedly stops granulosa cell proliferation and reduces the amount of cell mass that can
produce progesterone. Hence, the differences, while modest, are nevertheless statistically
different and fit with the clinical picture regarding pathogenesis. We have no reason to expect
that the patient groups differ with regard to progesterone secretion from the adrenal, so we
don’t expect this to account for the difference. We are thus left with the conclusion that the
difference in progesterone levels is most likely related to the presence of luteinized follicles.
Our findings are consistent with a process in which activated primordial follicles in these
patients grow in response to the high FSH levels acting on the FSH receptor. However, as a
result of the elevated LH levels (likely due to inadequate negative feedback related to
inadequate follicle cohort size), the tonic high LH levels induce inappropriately early
luteinization and thus impair normal follicle function.
Taken together these data have important implications with regard to potential therapies to
improve ovarian follicle function in those women with 46,XX spontaneous primary ovarian
insufficiency who have follicles remaining in the ovary. At present there are no established
therapies to improve ovulatory function in women with this condition (12,33–37). In women
with normal ovarian function the large cohort of atresia-destined follicles may play a more
important role than has been recognized (38). By providing negative feedback this cohort of
follicles maintains a proper gonadotropin environment, and thus prevents premature
luteinization (10,39,40).
Patients with follicles ≥ 8 mm at the time or our examination did not differ significantly with
regard to age at menarche from those who did not meet this criterion. However, patients with
follicles ≥ 8 mm were significantly older at the time of onset of menstrual irregularity,
significantly older at the time of diagnosis, and participated in our study significantly sooner
after diagnosis compared to patients without follicles ≥ 8 mm. However, regression analysis
supports a conclusion that the differences in hormone levels we demonstrated are real despite
these other differences. Possibly patients who had follicles ≥ 8 mm may represent a less severe
form of the disease.
Our study has limitations. It was not population based, and thus there may be inherent
acquisition bias that may limit application of these findings to all women with 46,XX
spontaneous primary ovarian insufficiency. The study was not blinded with regard to patient
or control, so there is possibility of bias accruing with regard to ovarian ultrasound
examinations. This would not be expected to have an effect on hormonal levels. Serial
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examination of follicles after FSH stimulation, measures of AMH or inhibin B, and Doppler
data on ovarian blood flow may have provided additional information. It is possible that with
a larger sample of patients we could have demonstrated a statistically significant increase in
serum estradiol levels in response to FSH stimulation. We, therefore, cannot conclude that all
of the follicles in these patients fail to respond, or respond minimally, to FSH stimulation.
Clearly, however, the response we observed is less than expected in these patients when
characterized as a group.
We conclude that in most cases 46,XX spontaneous primary ovarian insufficiency is not simply
a situation of complete ovarian follicle depletion. Nearly three-fourths of women with this
condition have antral follicles detectable by ultrasound. Furthermore, in nearly one-half of
these patients primordial follicles are capable of responding to endogenous FSH stimulation
as evidenced by growth to ≥ 8 mm in diameter and estradiol secretion. This, along with prior
evidence demonstrating the development of lutienized Graafian follicles in many of these
patients,(10) as well as the new evidence herein suggesting that follicles in these patients secrete
progesterone, support a conclusion that down regulation of FSH receptors is not the
predominant mechanism of follicle dysfunction in these patients. The present findings support
and extend prior evidence that inappropriate luteinization of follicles is the more likely
predominant mechanism. This would explain the resulting follicle dysfunction that 1)
prevented us from observing the expected increase in serum estradiol following exogenous
FSH administration, and 2) clinically impairs follicle growth to maturity and ovulation in these
patients. If inappropriate luteinization is the major underlying mechanism, then suppression of
the LH levels should improve ovulation and conception rates. There is a need for additional
prospective controlled studies designed to improve ovulatory function and fertility in women
with 46,XX spontaneous primary ovarian insufficiency.
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Figure 1.
Correlation between serum estradiol level and size of largest antral follicle detected by
transvaginal ultrasound in women with primary ovarian insufficiency who had a follicle of at
least 3 mm in diameter.
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Figure 2.
Serum estradiol response to stimulation with 300 IU FSH. (A) Control women, women with
primary ovarian insufficiency as a group, and women with primary ovarian insufficiency
segregated by the absence or presence of an antral follicle 8 mm in diameter or greater (***,
p < 0.0001 vs. baseline); B. Change in serum estradiol levels at 24 hours.
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Table 1
Baseline clinical characteristics of control women (N=42) and women with primary ovarian insufficiency (POI)
(N=97)
Characteristic Control Median (IQR) or N(%) POI Median (IQR) or N(%) P value
Age 37.0 (31.0, 42.0) 34.0 (28.0, 36.0) 0.003
BMI 22.7 (21.0, 24.7) 23.5 (20.9, 26.0) 0.158
Age at Menarche 13.0 (12.0, 14.0) 13.0 (12.0, 14.0) 0.335
Race % 0.119
 Asian 6 (14) 6 (6)
 African American 7 (17) 11 (11)
 Hispanic 3 (7) 3 (3)
 Caucasian 26 (62) 77 (79)
FSH (IU/L) 8.0 (7.0, 11.0) 81.0 (51.0, 111.0) <0.001
LH (IU/L) ND 49.0 (35.0, 68.0) --------
Estradiol (pg/mL) 36.3 (28.0, 57.0) 27.0 (20.0, 40.4) 0.019
Progesterone (ng/mL) ND 0.5 (0.3, 0.7) --------
Endometrial stripe (mm) 4.0 (3.0, 6.0) 2.0 (1.0, 3.0) <0.001
Right ovarian volume (cm3) 6.9 (5.8, 8.9) 1.4 (0.7, 2.6) <0.001
Left ovarian volume (cm3) 6.6 (4.4, 8.7) 1.4 (0.5, 2.4) <0.001
Largest follicle (mm) 9.0 (8.0, 11.0) 6.6 (2.3, 12.8) 0.003
Age at onset of menstrual irregularity N/A 28.4 (18.2, 32.9) --------
Age at POI diagnosis N/A 31.9 (25.3, 34.2) --------
Time since POI diagnosis (months) N/A 20.3 (5.8, 50.6) --------
IQR = Interquartile range, ND = Not done, NA = Not applicable
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Table 2
Baseline comparison of women with primary ovarian insufficiency segregated by the absence (N=52) or presence
(N=43) of a follicle of 8mm in diameter or greater and after statistical adjustment of hormone values for age, age
of onset of menstrual irregularity, age at diagnosis, and time since diagnosis.
Factor
<8mm follicle Median (IQR)
or N (%)
≥8 mm follicle Median (IQR)
or N (%) P value Adjusted P value
Age 31.5 (26.0,36.0) 34.0 (32.0,36.0) 0.063
BMI 24.4 (21.5,27.9) 22.6 (20.6, 25.4) 0.107
Age at menarche 13.0 (12.0, 13.0) 13.0 (12.0, 14.0) 0.976
Age at onset of menstrual irregularity 26.0 (16.0, 31.0) 31.5 (25.2, 33.3) 0.009
Age at POI diagnosis 29.0 (21.5, 33.4) 33.5 (30.8, 34.7) 0.002
Time since POI diagnosis (months) 27.4 (6.4, 74.9) 15.2 (4.8, 30.1) 0.029
Serum estradiol (pg/mL) 23.0 (20.0, 32.5) 39.6 (21.9, 80.9) <0.001 0.002
Serum progesterone (ng/mL) 0.5 (0.2, 0.6) 0.6 (0.5, 0.8) 0.002 0.004
FSH (IU/L) 93.0 (70.0, 115.0) 57.0 (33.0, 106.0) 0.001 0.002
LH (IU/L) 56.0 (42.0, 68.0) 37.5 (23.0, 68.0) 0.019 0.013
History of smoking 3 (6) 5 (12) 0.461
History of primary ovarian insufficiency in
family
9 (17) 12 (28) 0.227
Adrenal autoantibodies 0 (0) 3 (7) 0.089
History of thyroid disease 7 (14) 7 (16) 0.776
Race 0.424
 Asian 3 (6) 3 (7)
 African American 7 (13) 4 (9)
 Hispanic 3(6) 0 (0)
 Caucasian 39 (75) 36 (84)
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